Keywords
infection, antibodies
vaccination
SARS-CoV-2
pandemic
How to Cite
Abstract
Introduction: The quantitative assay called IgG II against SARS-CoV-2 has been available on the market since December 2020, and the nationwide vaccination of the population with Sputnik V began on December 29, 2020. Aim: To quantify the IgG anti-SARS-CoV-2 antibodies produced in women and men in response to vaccination with Sputnik V, and to evaluate whether they differ between patients who had the infection and those who did not and whether they differ between sexes. Materials and Methods: Postvaccination samples of the staff of the Rawson Hospital, Córdoba Province, Argentina, were collected 14, 42, and 60 days after the first dose of the Sputnik V vaccine. Samples were classified by sex and based on SARS-CoV-2 infections or not. The antibodies were quantified with the SARS-CoV-2 IgG Quant kit. The data were statistically analyzed with the software InfoStat using the Mann-Whitney test. The level of significance was 5%. Results: Sex would not be a differentiating factor in the concentration of antibodies in patients without previous infection (p>0.05) on days 14, 42, and 60 post-vaccination. Patients who had suffered the infectionshowed no significant differences on days 14 and 60 post-vaccination (p>0.05), but on days 42 post-vaccination (p<0.05). Conclusion: Different reports have concluded that a dose of vaccination in people previously infected with SARS-CoV-2 results in a significant increase in the concentration of antibodies and, thus, the second dose could be postponed. This would justify the vaccination with two doses for the people who did not suffer from the disease.
References
World Health Organization. WHO coronavirus 2019 (COVID-19) pandemic. [Internet]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019; 2021.
Centers for Disease Control and Prevention. COVID-19. [Internet]. [Consultado 21 ago 2021] Disponible en: https://www. cdc.gov/coronavirus/2019-ncov/index.html.
Chavez S, Long B, Koyfman A, Liang SY. Coronavirus Disease (COVID- 19): A primer for emergency physicians. Am J Emerg Med. 2021;44:220-9.
Long MJC, Aye Y. Science’s response to CoVID-19. Chem Med Chem. 2021;16(15):2288-314.
Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122-7.
Perfil de evolución clínica de las personas internadas con diagnóstico de COVID-19 asistidas en la Provincia de Córdoba. Actualización. Informe correspondiente al periodo del 06 de marzo al 4 de octubre de 2020. Comisión Clínica - Centro de Operaciones de Emergencia Provincia de Córdoba.
Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1).
Li T, Wei C, Li W, Hongwei F, Shi J. Beijing Union Medical College Hospital on “pneumonia of novel coronavirus infection” diagnosis and treatment proposal (V2.0). Med J Peking Union Med Coll Hosp. 2020.
Wastnedge EAN, Reynolds RM, van Boeckel SR, Stock SJ, Denison FC, Maybin JA, et al. Pregnancy and COVID-19. Physiol Rev. 2021;101(1):303-18.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-4.
Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7.
Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: Current state of the science. Immunity. 2020;52(6):910-41.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033-4.
Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020;323(22):2249-51.
Focosi D, Maggi F, Mazzetti P, Pistello M. Viral infection neutralization tests: A focus on severe acute respiratory syndromeβcoronavirus-2 with implications for convalescent plasma therapy. Rev Med Virol. 2021;31(2):1-11.
Amanat F, Stadlbauer D, Strohmeier S. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033-6. 17. Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther. 2004;10(4):616-29.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS. Safety an5 efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671-81.
Lineamientos técnicos y Manual del vacunador [Internet]. Argentina. gob.ar. 2021. Disponible en: https://www.argentina.gob.ar/coro navirus/vacuna/equipos-salud/lineamientos-manual-vacunador
Respuesta frente a la pandemia por SARS CoV 2 en Córdoba: detección de anticuerpos neutralizantes en individuos recuperados en el territorio de la provincia. [Internet]. [Consultado 17 Jul 2020]. Disponible en https://cordoba.conicet.gov.ar/respuesta-frente-a-lapandemia-por-sars-cov-2-en-cordoba/)
Universidad de Córdoba, Ministerio de Salud de Córdoba. Determinación de anticuerpos con el equipo comercial SARS-CoV-2 IgG II Quant (Abbott) como marcador subrogante de Anticuerpos Neutralizantes en potenciales donantes de PCC-19.
Empleo de la vacuna Sputnik V en Argentina: Evaluación de respuesta humoral frente a la vacunación. Informe parcial EneroβMarzo 2021 Ministerio de Salud de la Provincia de Buenos Aires,Ministerio de Ciencia, Tecnología e Innovación. Instituto Leloirβ CONICETβINBIRSβUNLP
Universidad de Córdoba, Ministerio de Salud de Córdoba. Evaluación de la respuesta de anticuerpos neutralizantes a la vacuna Sputnik V en una cohorte en Córdoba y evaluación de las propiedades neutralizantes de anticuerpos naturales y vacunales frente a la variante Manaos. [Internet]. Disponible en: https://www.cba.gov.ar/informesvacunacion-covid-19.
Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27(6):981-4.
Anichini G, Terrosi C, Gandolfo C, Gori Savellini G, Fabrizi S, Miceli GB, et al. SARS-CoV-2 antibody response in persons with past natural infection. N Engl J Med [Internet]. 2021;(NEJMc2103825). Disponible en: http://dx.doi.org/10.1056/nejmc2103825
Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T,
et al. Antibody response to first BNT162b2 dose in previously SARSCoV- 2-infected individuals. Lancet. 2021;397(10279):1057-8.
Tiberghien P, Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020;115(6):488-94.
Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID- 19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6):
Ogri M, Žigon P, Podovšovnik E, Lakota K, Sodin-Semrl S, Rotar Ž, et al. Differences in SARS-CoV-2-specific antibody responses after the first, second, and third doses of BNT162b2 in naïve and previously infected individuals: A 1-year observational study in healthcare professionals. Front Immunol. 2022- [Internet]. Disponible en: http://dx.doi.org/10.3389/fimmu.2022.876533
Ibarrondo FJ, Hofmann C, Fulcher JA, Goodman-Meza D, Mu W, Hausner MA, et al. Primary, recall, and decay kinetics of SARS-CoV-2 vaccine antibody responses. ACS Nano. 2021;15(7):11180-91.
Krammer F, Srivastava K, Simon V, the PARIS team. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine [Internet]. bioRxiv. 2021. Disponible en: http://dx.doi.org/10.1101/2021.01.29.21250653
Naesens R, Mertes H, Clukers J, Herzog S, Brands C, Vets P, et al. SARS-CoV-2 seroprevalence survey among health care providers in a Belgian public multiple-site hospital. Epidemiol Infect. 2021;149(e172).
Scohy A, Gruson D, Simon A, Kabamba-Mukadi B, De Greef J, Belkhir L, et al. Seroprevalence of SARS-CoV-2 infection in health care workers of a teaching hospital in Belgium: self-reported occupational and household risk factors for seropositivity. Diagn Microbiol Infect Dis.2021;100(4):115414.